Develop microfluidic biochip technologies for precision oncology. Provide tools for early cancer detection, diagnosis, and treatment monitoring. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
This grade is a blend: the profit side is strong, the sales tempo slow.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $2.9M in the vault; even if every debt were paid off, $1.6M would remain.
A loss of $102K against $0 in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 48/100.
As the slice kept from each sale thins out, so does the profit.
On our five-subject report card, ADVB sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ADVB is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.